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Abstract
Background: Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging.
The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were
designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein signalling, contributing to tumour
progression. The oncogenic potential of ErbB receptors unfolds in case of overexpression or mutations. Dimerisation
with other receptors allows to bypass pathway blockades. Our intention is to reconstruct the ErbB network to reveal
resistance mechanisms. We used longitudinal proteomic data of ErbB receptors and downstream targets in the ErbB-2
amplified breast cancer cell lines BT474, SKBR3 and HCC1954 treated with erlotinib, trastuzumab or pertuzumab,
alone or combined, up to 60 minutes and 30 hours, respectively. In a Boolean modelling approach, signalling
networks were reconstructed based on these data in a cell line and time course specific manner, including prior
literature knowledge. Finally, we simulated network response to inhibitor combinations to detect signalling nodes
reflecting growth inhibition.
Results: The networks pointed to cell line specific activation patterns of the MAPK and PI3K pathway. In BT474, the
PI3K signal route was favoured, while in SKBR3, novel edges highlighted MAPK signalling. In HCC1954, the inferred
edges stimulated both pathways. For example, we uncovered feedback loops amplifying PI3K signalling, in line with
the known trastuzumab resistance of this cell line. In the perturbation simulations on the short-term networks, we
analysed ERK1/2, AKT and p70S6K. The results indicated a pathway specific drug response, driven by the type of
growth factor stimulus. HCC1954 revealed an edgetic type of PIK3CA-mutation, contributing to trastuzumab inefficacy.
Drug impact on the AKT and ERK1/2 signalling axes is mirrored by effects on RB and RPS6, relating to phenotypic
events like cell growth or proliferation. Therefore, we additionally analysed RB and RPS6 in the long-term networks.
Conclusions: We derived protein interaction models for three breast cancer cell lines. Changes compared to the
common reference network hint towards individual characteristics and potential drug resistance mechanisms.
Simulation of perturbations were consistent with the experimental data, confirming our combined reverse and
forward engineering approach as valuable for drug discovery and personalised medicine.
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Background
Longitudinal time course data are the basis for modelling
signalling networks in a holistic systems biology approach
in order to uncover mechanisms of signal transduction
dynamics [1,2]. Network models provide novel insight
[3,4] and allow us to perform efficiently simulations to
predict systems behaviour or evaluate certain hypotheses
[5]. Furthermore, combining perturbation experiments
with the measurements of system dynamics seems to
be even more efficient than time series data on their
own [6-8]. Knock-outs or stimuli as directed perturba-
tions support the systematic identification of regulatory
relationships.
Quantitative models, based on differential equations,
require explicit knowledge on the kinetics of the sys-
tem of interest [9-12]. In contrast, the qualitative Boolean
abstraction considers the components’ states as binary
variables, being either active (1) or passive (0), but nev-
ertheless encompasses the essential functionality [13,14].
Wang et al. stressed, that Boolean models have already
been successfully applied in reverse engineering of pro-
teomic signalling networks, and their reduced complexity
is considered to be especially advantageous for large-
scale systems [15]. To avoid the drawbacks of purely data-
or literature-driven algorithms regarding completeness,
generalisation or interpretability, combined approaches
become more and more prominent in the area of net-
work reconstruction [6,16,17]. Some reverse engineering
approaches, like ddepn [6] or CellNOptR [18], ideally join
perturbed time course input data and literature prior
knowledge in network reconstruction, while preserving
the simplicity of Boolean logic at the same time. Forward
engineering methods allow subsequent analysis of the sta-
ble states of the reconstructed system. Hence, this may
allow to deduce possible long-term behaviour of compo-
nents activity under perturbations. Such approaches are
integrated and freely available in the open source Python
software package BooleanNet [19] or in the R [20] pack-
age BoolNet [21], for example. As reviewed by Samaga
and Klampt [22], several software tools can be applied for
the dynamic modeling of logical signal transduction net-
works. Among others, they exemplarily mentioned GIN-
sim [23], SQUAD [24], BooleanNet [19],ChemChains [25],
Odefy [26], and BoolNet [21].
Here we focus on protein signalling networks in breast
cancer, representing the most common cancer type
among women [27]. Breast cancer, as a heterogeneous
disease, can be divided into subgroups, which differ in
cellular properties as well as in prognosis. This requires
individual therapy approaches, which are in the focus of
current research and have partially already been realised.
Here we are interested in the ‘HER2-positive’ subtype
of breast cancer, overexpressing the human epidermal
growth factor receptor 2 (HER2, also termed ErbB-2).
ErbB-2 is a receptor tyrosine kinase (RTK) and mem-
ber of the epidermal growth factor (EGF) receptor family,
consisting of three further RTKs, namely ErbB-1, ErbB-3
and ErbB-4. These receptors cooperatively function as
homo- or heterodimers after activation via growth fac-
tors like EGF for ErbB-1 or heregulin (HRG) for ErbB-3
[28]. This initialises signalling cascades, pathologically
contributing to tumourigenesis and tumour progression.
Interestingly, different dimer formations induce different
signalling pathways, like PI3K and MAPK, also with dif-
fering signalling strengths [29]. The role of the orphan
receptor ErbB-2 in dysregulation of the ErbB network
is of major interest, due to its overexpression in 10-
20% of breast tumours, diagnosed as HER2-positive.
Furthermore, its role as favoured dimerisation part-
ner independent on ligand-activation implies oncogenic
potential [30-32]. The therapeutic antibodies trastuzumab
and pertuzumab have especially been designed to target
ErbB-2 [33].
However, frequently occurring therapy resistance
reduces the efficiency of targeted therapeutics [34-36].
This resistance is often associated with deregulated path-
way activity [37,38] or bypasses via other RTKs, especially
ErbB family members [39]. Mainly ErbB-1 expression has
been anticipated as molecular cause to overcome impact
of ErbB-2 targeting drugs. Small-molecule inhibitors such
as erlotinib are already in use against non-small cell lung
cancer [40] and pancreatic cancer [41].
Here we aim as a first step at the identification of
individual drug response patterns and insights into drug
resistance in HER2-positive breast cancer. ErbB-2 ampli-
fied cell lines were therefore subjected to short- and
long-term drug treatment with erlotinib, pertuzumab and
trastuzumab, alone or in combinations. Samples were
analysed by reverse-phase protein arrays (RPPA) [42].
We were interested in synergistic benefits of combining
erlotinib, pertuzumab or trastuzumab in ErbB-1 express-
ing, ErbB-2 amplified tumours with differing resistance
phenotypes. Therefore three representative breast cancer
cell lines were selected as model systems, namely BT474,
SKBR3 and HCC1954, of which the latter is known to be
trastuzumab resistant due to a PIK3CA mutation, while
BT474 exhibits wild type behaviour [43]. The SKBR3 cell
line is supposed to be pertuzumab resistant [44].
ErbB dimers predominantly activate the MAPK and
PI3K pathway [29]. Therefore, we concentrated on the
involved key regulators in fast downstream signalling.
Among those were ERK1/2 and AKT, and also p70S6K,
which is upstream influenced by both of the signalling
axes. Phosphorylation of RPS6 and RB was used as long-
term indicator for proliferation, cell cycle or tumour
progression [28]. Prior literature knowledge on ErbB sig-
nalling was used as input for protein network reconstruc-
tion per cell line via ddepn. Beyond that, we inferred
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combined therapies that target ErbB familymembers, cus-
tomised to the topology of the different subtypes. BoolNet
was applied to compute stable cycles of protein activ-
ity states, so-called attractors, incorporating all possible
treatment combinations. This way, optimal drug treat-
ment to deactivate oncogenic proteins was identified.
Methods
Data
Protein abundance and phosphorylationmeasurements in
BT474, SKBR3 and HCC1954 cells were carried out as
described by Henjes et al. [28]. In principle, the RPPA pro-
tein array technology works as follows. Minimal amounts
(1 nl volume) of cell lysate are spotted along with a serial
dilution of control samples on nitrocellulose-coated glass
slides using a printing robot (Aushon 2470 arrayer). Sam-
ples are organised as ordered subarrays so that they are
addressable during the data analysis procedure, and a sin-
gle slide can accommodate one or more subarrays. Each
subarray is analysed using a highly specific detection anti-
body to measure the abundance of a certain protein or its
phosphorylation rate. For each spot, the ratio of bound
detection antibody is visualised using secondary antibod-
ies labelled with near infrared (NIR) fluorescent dyes.
Slides are scanned using the Odyssey scanner (LiCor Bio-
sciences). Spot intensities are determined using amicroar-
ray image analysis software (GenePix).
Apart from the quantitative character, another advan-
tage of the technology is the handling of large sample sets
which protein abundance can be detected simultaneously
in a high throughput fashion. 20-200 identical slides can
be produced in parallel in a single print run.
In order to normalise the data spot-wise for deviant total
protein concentrations due to spotting variance, staining
with Fast Green FCF dye was employed [42]. There-
fore, one slide was stained with the dye to determine the
total protein content of each lysate spot and correspond-
ing signal intensity correction factors. The spots on the
remaining slides were divided by these correction factors
and afterwards multiplied by the median value to scale the
data back to the native range.
The RPPA data used here include data presented in
Henjes et al. [28]. Additionally, further targets have been
measured and were used for network reconstruction. The
complete data set has been submitted to the Gene Expres-
sion Omnibus (GEO) with accession number GSE50109.
Short-termmeasurements
In the short-term measurements, trastuzumab, per-
tuzumab and erlotinib were added to the cells in starva-
tion medium one hour before stimulation with the growth
factors EGF and HRG. All possible 24 combinations of
drugs and stimuli were measured. Application of the stim-
uli was defined as time point zero in the measurements.
The growth factors were chosen to activate explicitly the
MAPK and PI3K pathway. Lysate preparation was per-
formed at ten time points, namely after 0, 4, 8, 12, 16,
20, 30, 40, 50 and 60 minutes. The drug treatment exper-
iments comprised three biological replicates, whereas the
inhibitor-free experiments incorporated five biological
replicates. The experiments for the SKBR3 cell line com-
prised only two biological replicates of HRG stimulated
cells under the triple drug combination. Each biological
replicate was spotted in triplicate on the RPPA slides.
To obtain short-term signal intensities, eleven antibodies
for specific phosphorylation sites were selected according
to quality checks, including inspection of corresponding
dilution series and comparison to signals arising from sec-
ondary antibodies only. The chosen target proteins and
respective antibodies are listed in Additional file 1.
Long-termmeasurements
For long-term measurements, no explicit ligand stimu-
lation was performed. Instead, cells were incubated in
full growth medium for 24 hours prior to adding the
three mentioned therapeutics in double combinations or
as triplet. Single drug treatment was just conducted with
erlotinib. Full growth medium was used to avoid con-
founding effects of nutrient deficiency. Protein abundance
was also quantified without any drug application. The
measuring points included 0, 1, 2, 4, 6, 8, 12, 18, 24 and 30
hours with three biological and technical replicates each.
At time point 18, only two biological replicates were avail-
able. Additional file 1 displays the 21 targets of interest for
long-term signalling.
Statistical inference of drug effects
To determine, whether a specific drug treatment revealed
an inhibiting effect on the signal intensities of the proteins,
we applied the following method. Firstly, for each protein
and (combinatorial) drug treatment we linearly modelled
the signal intensities as depending on the factors time and
group, i.e. no drug treatment versus drug treatment. If the
interaction of both factors showed a significant (p-value<
0.05) influence on the signal intensity, we further applied
a Wilcoxon rank sum test for the measurements at time
point 60 minutes for the short-term data, or at time point
30 hours for the long-term data. Thereby, we tested for
significantly (p-value < 0.05) smaller intensity values in
the drug treated group. The drug treatments with a sig-
nificant test result were considered as efficient inhibitors.
The therapeutic (combination) with the smallest p-value
was defined as the optimal one.
Literature prior knowledge
Wemanually determined two reference networks, i.e. one
for each time course, as initial joint hypotheses for all
of the three breast cancer cell lines. Because emphasis
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was put on phosphoproteomic signalling, this was mainly
based on PhosphoSitePlus® [45]. Several publications con-
firm these assumptions, as depicted in Additional file 2.
Network reconstruction
For Boolean network reconstruction, we chose the
method of dynamic deterministic effects propagation net-
works (DDEPN) [6]. Thismethodwas particularly tailored
to perturbed longitudinal protein phosphorylation data.
It is based on the DEPN approach [46], which stands for
deterministic effects propagation networks. The deter-
minism is related to the way of perturbation effect prop-
agation in the networks from parent to child nodes,
implying transitively closed graphs. The dynamic version
of Bender et al. [6,47] differs with respect to the integra-
tion of perturbed time course measurements. While the
DEPN approach requires many perturbations, like knock-
downs, but only few time points, which are regarded as
independent measurements, ddepn is designed for longer
time series without the necessity of many or all network
nodes being perturbed. The latter situation, i.e. few per-
turbations by drug interventions, reflected the design of
the RPPA experiments under consideration here, hence
leading to the application of ddepn. Most network recon-
struction algorithms have been designed for gene expres-
sion data frommicroarray measurements [7], which differ
from (phospho-)protein data regarding the amount of
involved network nodes. Many current methods are tai-
lored to the inference of gene regulatory networks based
on static measurements at one time point, reflecting the
steady state of the system under consideration [48]. The
longitudinal time course data used here require a suitable
method, as provided by ddepn. The method of Bender
et al. was shown to outperform two dynamical Bayesian
network approaches, and to be capable of inferring known
signalling cascades in the ErbB pathway [47]. A further
advantage was the public availability of ddepn as an R [20]
package.
The reconstruction procedure is depicted in Additional
file 3, and the core elements are described according
to [6,47] in the following. The protein interaction net-
works are modelled as directed, possibly cyclic, graphs,
with nodes V = {vi : i ∈ 1, . . . ,N} representing proteins
and edges representing interactions. Also the external per-
turbations, i.e. the drugs and growth factors in our case,
are modelled as nodes. The edge types can be either acti-
vating or inhibiting, denoted by 1 and -1, respectively,
in the adjacency matrix  = V × V → {0, 1,−1} of
the network. An entry of zero indicates no edge between
two nodes. So each edge incorporates a pair of nodes{
φij : i, j ∈ 1, . . . ,N
}
. The measurement data, which form
the basis for the reconstruction, are stored in a matrix
D = {ditr : i ∈ 1, . . . ,N , t ∈ 1, . . . ,T , r ∈ 1, . . . ,R}, consid-
ering T time points and R replicates.
For the inference of a network structure, optimally
fitting to the data, we applied the stochastic Markov
Chain Monte Carlo (MCMC) approach of ddepn, called
inhibMCMC, in which the space of possible networks
is sampled, based on posterior probabilities. It extends
a Metropolis-Hastings type of MCMC sampler by the
capability of sampling two edge types directly, i.e. acti-
vation and inhibition. The posterior distribution of a
network  given the data D, is defined as P(|D) =
P(D|)P()
P(D) ∝ P(D|)P(), with P() as the prior prob-
ability distribution and P(D|) as the likelihood of the
data given the network. The latter is defined in [47]








where ∗ = {γ ∗itr : i ∈ 1, . . . ,N , t ∈ 1, . . . ,T , r ∈ 1, . . . ,R}
denotes the optimized system state matrix, containing
active and passive states per protein and time point. It is
estimated in the following way. Assuming that the pro-
teins can be either active (1) or inactive (0), signalling
dynamics are modelled by Boolean signal propagation
for a given network. All nodes, except the permanently
active perturbations, are therefore initialised with inactive
states. The transition rule is that children nodes get acti-
vated if at least one activating parent node is active and
all inhibiting ones are inactive. In this way, all reachable
system states are computed and stored in a matrix  =
{γik ∈ {0, 1} : i ∈ 1, . . . ,N , k ∈ 1, . . . ,M}, holding column-
wise the activation states of all proteins at transition step
k. The amount of transitions is limited by 0 < M ≤ 2N .
This state matrix has to be optimized, as it is not related
to the measured time points yet. The true unknown state
sequence over time is represented by ∗, which is esti-
mated by a hidden Markov model (HMM). The resulting
ˆ∗ indicates whether a data point ditr has an underlying
active (1) or passive (0) normal distribution
ditr ∼
{
N (μi0, σi0), if γˆ ∗itr = 0
N (μi1, σi1), if γˆ ∗itr = 1.
The distribution parameters are for each protein esti-
mated as empirical mean and standard deviation of all
measurements for the considered protein in the cor-
responding class, yielding the parameter matrix ˆ ={
θˆi0, θˆi1
}
= {(μˆi0, σˆi0), (μˆi1, σˆi1)} ∀i ∈ 1, . . . ,N .
The prior probability distribution P() includes penali-
sation of differences between the network structure and
a user-defined prior belief B = V × V →[−1, 1], where
the absolute value correlates with the confidence in an
edge. Here we chose B = V × V → {0, 1,−1}, assum-
ing in advance specific activating, inhibiting or missing
edges with maximum confidence. We made use of the
Laplace prior model (laplaceinhib), accounting for both
edge types, i.e. activation and inhibition. The prior belief
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ing a weighted difference term 
ij = |φij − bij|γ with a
weight exponent γ ∈ R+. As the edge probabilities are
assumed to be independent, the prior belief for a net-
work structure  is derived as the product of those, i.e.
P(|B, λ, γ ) = ∏
i,j
P(φij|bij, λ, γ ), i, j ∈ {1, . . . ,N}. The
individual edge probabilities lie between 0 and 12λ ∀λ, γ ∈
R
+. The protein interactions corresponding to our cho-
sen prior are displayed in Additional file 2. The prior’s
impact strength was emphasised in such a way, that only
strongly deviating data influence the network structure,
because the ErbB wiring as well as the MAPK and PI3K
pathways are well examined in literature. This prioritisa-
tion is reflected in the hyperparameter λ set to 0.0001. For
the parameter γ we chose one, neglecting extra penali-
sation of deviation from the prior. These settings should
preserve robustness, but at the same time allow enough
impact strength of strongly differing data values.
The network inference via inhibMCMC spanned 50,000
iterations with the first 25,000 iterative steps as burn-in
phase. To ensure convergence, ten parallel MCMC chains
were run, each initialised with a starting network. Con-
vergence was validated via Gelman diagnostic [49]. Nine
of the initial ten networks were randomly generated, i.e.
for the defined nodes activating, inhibiting or no edges
were sampled. The remaining network assumed no con-
nections between the nodes. These initial networks were
pruned to the following constraints. Firstly, the nodes
related to the growth factors and drugs must not have
any ingoing edges. Above that, the indegree of all nodes
was limited to four. Finally, no self-loops were allowed.
To find significantly occurring edges among the indepen-
dent runs, merging into a consensus network, a Wilcoxon
rank sum testing procedure was used. In detail, in each
run the amount of sampled activations and inhibitions per
edge was counted and divided by the total number of sam-
pled edges. Subsequently the null-hypothesis was tested,
whether the means of these ten edge-specific confidence
values equal the same for activation and inhibition. In case
of not rejecting the null-hypothesis, coming along with an
adjusted p-value exceeding the significance level α = 0.05,
no edge was assumed. Otherwise, the respective alter-
native determined the type of interaction. Adjustment
for multiple testing followed the method of Benjamini
and Hochberg, controlling the false discovery rate [50].
The whole procedure was embedded into a leave-one-
out cross-validation approach. So each of the ten MCMC
chains was left out once, and the testing algorithm was
applied to the remaining runs. An edge was included in
the final consensus network if it occurred in all of the
cross validation runs. Finally, to prevent excessive spuri-
ous or obsolete connections ascribable to transitivity, as
argued by Bo Na Ki et al. [51], newly reconstructed edges
were successively added to the prior network according to
ddepn significance and fit of resulting attractor states to
the observations of Henjes et al. [28].
Perturbation simulations
To figure out which input of drug combination leads to
a certain attractor state of the reconstructed network
system, the R package BoolNet [21] was applied. Themoti-
vation was based on the assumption that attractors, rep-
resenting cycles of states, comprise the stable states of cell
function. In those states networks mostly reside. Hence,
they mirror system phenotypes, dependent on the pertur-
bation context. To the best of our knowledge, apart from
BoolNet, there are hardly any R packages offering attractor
calculations for Boolean networks. This package supports
import of networks in form of files containing Boolean
formulas. So it could be easily integrated in our workflow
as subsequent analysis step after network reconstruction.
We used its functionality to identify attractors in a syn-
chronous and an asynchronous way. The resulting attrac-
tors were steady-state attractors. These consist of only
one state, in which all transitions from this state result.
These attractors are identical for synchronous and asyn-
chronous updates. We focused on the steady-states, as
these should reflect the homoeostatic system state of the
cell lines. Intermediate transition states would be interest-
ing as well, but due to the large amount of the involved
targets, it would have been too complex to analyse those
here in detail.
The search started from predefined initial states of
the network nodes. The drug and growth factor nodes
were fixed to specific values, reflecting the conducted
experiment to be simulated. For short-term signalling,
perturbations included all possible combinations of the
therapeutics under the combined stimulus of EGF and
HRG. Although the data of separate stimulation with EGF
and HRG was used for network reconstructions, here we
focused on the combined treatment, representing a more
natural tumour environment than a single growth factor
alone. Two possible binary states, i.e. active (1) or pas-
sive (0), to the power of three different drugs led to eight
possible combinations. These were used as fixed input
conditions, as the effect was assumed to be continuously
valid. Analogously, the growth factors were permanently
fixed to one. The remaining protein activity start states
were initialised with zero. These components were flexi-
ble towards updates. In the long-term measurements, no
growth factors were involved but full growth medium.
This was defined as one stimulating input S, initially acti-
vating the ErbB receptors. This also led to eight fixed input
combinations.
BoolNet expects network representation in form of log-
ical interaction rules as input. In contrast, ddepn deliv-
ers network reconstruction output in terms of adjacency
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matrices. Therefore, we incorporated an interface func-
tion into the ddepn package, called adjacencyMa-
trix_to_logicalRules. In detail, the loadNetwork function
of BoolNet requires a file containing row-wise logical acti-
vation rules of each network node. Each row looks like
‘target node, (activator_1 | activator_2) & !(inhibitor_1 |
inhibitor_2)’, here exemplary for a node with two ingo-
ing activating and inhibiting edges each. The logical OR
operator is encoded by ‘|’, the logical AND is encoded
by ‘&’, and logical negation is represented by ‘!’. Accord-
ingly, all of the A inferred activating nodes V+ =
{va : a ∈ 1, . . . ,A, A < N} of a target node vj, represented
by an adjacency matrix entry φaj = 1, and vj itself were
connected via OR operators. This ensured that at least one
of the activators or the target protein itself had to be active
to activate the target node. Analogously, the I inhibiting
nodes V− = {vi : i ∈ 1, . . . , I, I < N} with φij = −1 were
connected via OR operators. A logical negation opera-
tor was attached to ensure that the activity of one of the
nodes vi would result in an inactive node vj. Both sets
of activators and negated inhibitors were then connected
via a logical AND operator. After conversion of the adja-
cency matrices to logical rules, those were implemented
in BoolNet into a computational model, to perform per-
turbation simulations per cell line and time course as well
as subsequent analyses of the resulting attractor states.
Results and discussion
The complete workflow, holding for both, short- and
long-term analysis, is depicted in Figure 1. For a better
understanding of the discussion on MAPK and PI3K sig-
nalling, Figure 2 displays the interactions between the
main MAPK and PI3K targets of the ErbB prior net-
works. It shows the preferred pathway activations by all
possible homo- and heterodimers formed upon ligand
binding to the ErbB-1 and ErbB-3 receptors [9,29,52-54].
The confidence values, representing the likeliness of the
reconstructed network edges, are shown in Additional
file 4.
Short-term signalling network reconstruction
The short-term signalling networks, reconstructed by the
ddepn algorithm, are depicted in Figure 3. The equivalent
Boolean logical interaction rules are listed in Additional
file 5. In comparison to the prior network, newly inferred
edges were specific for each cell line, and all of them
were activating. For HCC1954 and BT474, seven addi-
tional edges were reconstructed, while in SKBR3 only two
new edges were reconstructed. No prior edge deletion or
type reversal took place.
HCC1954 is driven by the PI3K as well as theMAPK pathway
In HCC1954, the new edges contributed to both, PI3K
and MAPK, signalling. The interaction ErbB-1→ErbB-2
reflected a dominant role of heterodimerisation of both
receptors, as described by Henjes et al. [28]. The fact
that it was specifically inferred for HCC1954, pointed
to hyperactive ErbB-1/2 heterodimers here. These are
known to trigger the MAPK but also, to a lesser extent,
the PI3K pathway. The link PDK1→MEK1/2, supported
by Sato et al. [55], stressed crosstalk between these path-
ways, placing PDK1 into a key position in the PI3K
pathway, and MEK1/2 in the MAPK pathway, respec-
tively. Two of the new edges in HCC1954, PDK1→ErbB-2
and p70S6K→AKT, contributed to feedback loops, which
were not present in the other two cell lines. Such a
topological network element could stabilise the known
trastuzumab resistance by boosting the oncogenic effect
of ErbB-2 and the mutant hyperactive PI3K pathway. Evi-
dence for the feedback mechanism involving PDK1 was
provided by Maurer et al. [56] and Tseng et al. [57]. Vega
et al. noted an indirect activation of AKT by p70S6K via
mTOR [58].
BT474 is driven by the PI3K pathway, while SKBR3 is driven by
theMAPK pathway
Comparably to HCC1954, in BT474 an edge indicat-
ing hyperactive heterodimers was found, namely ErbB-
3→ErbB-2, here interestingly with a strong impact on
AKT [28]. BT474 is known to contain a rare type
of PIK3CA mutation [43]. Pathway crosstalk was also
observed in BT474, but hereMEK1/2 activated PDK1, and
not vice versa like in HCC1954. This edge was supported
by Frödin et al. [59], underlining dominant PI3K signalling
in this cell line.
The newly detected interactions in SKBR3 started from
ErbB-3 and PDK1, and both activated ERK1/2. This
reflected a dominant MAPK pathway, in which ErbB-
3→ERK1/2 was interpretable as indirect stimulation of
ERK1/2 via MEK1/2, activated by ErbB-2/3 dimers [55].
Perturbation simulations on short-term networks
Perturbations included all possible combinations of
the therapeutics erlotinib, pertuzumab and trastuzumab
under combined stimulation of EGF and HRG. All
inferred attractors were simple and consisted of one
steady-state. This means that all transitions from this state
result in the state itself. Table 1 summarises all simula-
tion outcomes for the attractors of the AKT and ERK1/2
proteins, as those are key players in the PI3K (AKT) and
MAPK (ERK1/2) pathways. Additionally, the results for
p70S6K are listed there, as both pathways regulate this
protein [60].
Stimulation with EGF and HRG should result in acti-
vation of ErbB-1 and ErbB-3, followed by dimerisation
amongst ErbB members. This should initialise signalling
cascades in the MAPK and PI3K pathways (Figure 2).
Indeed, AKT, ERK1/2 and p70S6K got activated in
von der Heyde et al. BMC Systems Biology 2014, 8:75 Page 7 of 21
http://www.biomedcentral.com/1752-0509/8/75
Figure 1Modelling workflow. The figure summarises the applied modelling approach. RPPA data of three individual breast cancer cell lines were
generated under short- and long-term drug treatment. They constituted the basis for network reconstruction in combination with prior literature
knowledge about protein wiring. The reconstructed networks per cell line and time course in turn underwent Boolean perturbation simulations to
reveal optimal drug treatments.
all cell lines, which was revealed by simulations as
well as observations in graphical analyses (Table 1,
Figures 4, 5, 6).
As we were interested in identifying optimal drug treat-
ments, Table 2 summarises the corresponding statistical
results. Most of them were supported by the perturbation
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Figure 2 Scheme of ErbB dimers related MAPK and PI3K pathway activation. The figure depicts the different homo- and heterodimers of ErbB
receptors, induced upon activation via the ligands EGF or HRG. The active dimers then initialise the MAPK and PI3K signalling cascades. The orange
(PI3K) and green (MAPK) arrows denote, which dimer activates which pathway.
simulation results, corresponding to attractor states of
AKT, ERK1/2 and p70S6K being zero. Four main con-
clusions were drawn from these results, which will be
discussed in detail in the following subsections. Firstly,
inhibition of PI3K signalling, reflected by downregulated
AKT, required the combined treatment with erlotinib,
pertuzumab and trastuzumab. Secondly, inhibition of the
MAPK pathway, represented by ERK1/2, was reached
with erlotinib alone in SKBR3 and HCC1954. BT474 addi-
tionally needed pertuzumab. Thirdly, the protein activity
of p70S6K was influenced by both, PI3K and MAPK,
pathways. The drug response differed between cell lines,
indicating both pathways contribute to a different extent.
Finally, the drug effect on PI3K signalling was much better
in SKBR3 than in HCC1954, pointing to resistance in the
latter cell line.
Inhibition of PI3K signalling requires drug combinations
In SKBR3, the triple drug combination was most effec-
tive in inhibiting AKT (Figure 4, Table 2). In BT474,
pertuzumab combined with erlotinib was most effi-
cient, but AKT signalling was not fully suppressed as
in SKBR3 (Figure 5). Statistically, we did not infer any
significant positive drug effect in this cell line. Obvi-
ously, erlotinib in synergistic combination with at least
pertuzumab was needed to block the ErbB-2 receptor
and its heterodimerisation, mainly with ErbB-1, but also
ErbB-3. The HRG activated ErbB-2/3 heterodimers and
PI3K pathway in BT474, as revealed by the network
reconstructions, might have prevented a potent drug
efficacy.
Interestingly, BT474 and SKBR3 required pertuzumab.
This drug was especially designed to prevent het-
erodimerisation with ErbB-2. The stimuli EGF and HRG
together activate PI3K signalling by ErbB-2/3, ErbB-
1/2 and ErbB-1/3 dimers (Figure 2). The need for
pertuzumab combined with erlotinib indicated an impor-
tant role of ErbB-1/2 dimers. This was supported by the
fact, that in HCC1954 with dominant heterodimers of
this type, as revealed by network reconstructions, none
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Figure 3 Reconstructed short-term signalling networks. The figure displays the reconstructed short-term signalling networks coloured
according to the preserved prior reference network (black) and newly inferred (added) individual edges per cell line. Target proteins are represented
as rectangles with stimuli and drugs coloured in red. The three drug names erlotinib, trastuzumab and pertuzumab are abbreviated via their first
letters. Solid arrows denote activating interactions while dashed ones represent inhibitions.
Table 1 Attractor states of short-term perturbation simulations
BT474 HCC1954 SKBR3
Simulation AKT ERK1/2 p70S6K AKT ERK1/2 p70S6K AKT ERK1/2 p70S6K
A E A E A E A E A E A E A E A E A E
X 1 1 1 1 1 1 1 1 1
E 0 1 1 0 1 0 1 0 1 0 1 0 0 1
P 1 1 1 0 1 0 1 0 1 0 1 0 1 0 1
T 1 1 1 1 1 1 1 1 1
E, P 1 1 0 1 0 1 0 0 1 0 0 0 0 1
E, T 0 1 1 0 1 1 0 1 1 0 1 0 0 1
P, T 1 1 1 0 1 0 0 1 0 0 0 1
E, P, T 1 1 0 1 0 1 0 0 1 0 0 0
The therapeutics erlotinib, trastuzumab and pertuzumab, abbreviated by first letters, that were permanently active besides EGF and HRG in the simulated
perturbation conditions are stored in the column Simulation. No simulated drug treatment is denoted by ‘X’. The A columns hold the attractor states of the proteins
AKT, ERK1/2 and p70S6K, associated with the perturbations. The E columns contain the protein activity status, statistically deduced from the experimental data. In case
of a significant (p-value< 0.05) combined influence of both, drug treatment and time, on the protein signal intensity, a Wilcoxon rank sum test was conducted for the
measurements at time point 60 minutes. The drug treatments leading to significantly (p-value< 0.05) smaller intensity values compared to the control measurement
‘X’ were considered as efficient inhibitors, resulting in a table entry of zero. Consistency between simulations and experimental observations is printed in bold.
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Figure 4 SKBR3 short-term time courses of AKT, ERK1/2 and p70S6K. The figure shows splines and related standard error bars of the measured
RPPA data for AKT, ERK1/2 and p70S6K after combined EGF and HRG stimulation in the SKBR3 cell line. The measurements included ten time points
up to 60 minutes. The different drug treatments are marked by different colours with ‘X’ denoting no drug treatment.
of the drugs was likewise efficient in inhibiting AKT
(Figure 6). However, the optimal effect was revealed for
the triple drug combination (Table 2). The simulations
suggested pertuzumab alone or a combination of both
monoclonal antibodies (Table 1). It has to be kept in
mind, that the attractor states resembled a long-term
steady state, which can differ from observations up to 60
minutes.
The perturbation simulations in BT474 did not lead to
inactive AKT upon combined pertuzumab and erlotinib
treatment. Instead, erlotinib alone or combined with
trastuzumab was efficient (Table 1). Nevertheless, this
supported the need for the small molecule inhibitor
and a monoclonal antibody to suppress ErbB-2 induced
PI3K signalling. In SKBR3, the attractor states con-
firmed the described optimal drug treatment to deactivate
AKT. Trastuzumab, when applied alone, was the only
treatment without a positive effect in the simulations
(Table 1).
Inhibition of MAPK signalling requires erlotinib
Signalling through the MAPK pathway, represented by
ERK1/2 activation, was efficiently inhibited by erlotinib
alone in both, HCC1954 (Figure 6, Table 2) and SKBR3
(Figure 4, Table 2), cell lines. EGF activates the MAPK
pathway via ErbB-1 homodimers and ErbB-1/2 het-
erodimers (Figure 2). Both are prevented by ErbB-1 inhibi-
tion via erlotinib, which was especially designed to target
this receptor.
In BT474, pertuzumab plus erlotinib was required
(Figure 5, Table 2). This was analogous to the situation in
PI3K signalling.
HRG activates the MAPK pathway via ErbB-2/3 het-
erodimers (Figure 2). Obviously, BT474 needed the
addition of the monoclonal antibody due to dominant
ErbB-2/3 formation and activity. On the contrary, the
other two cell lines just needed erlotinib alone. Here, in
addition to the ErbB-1 dimers, the ligand-independent
ErbB-2 homodimers might have driven ERK1/2 activation
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Figure 5 BT474 short-term time courses of AKT, ERK1/2 and p70S6K. The figure shows splines and related standard error bars of the measured
RPPA data for AKT, ERK1/2 and p70S6K after combined EGF and HRG stimulation in the BT474 cell line. The measurements included ten time points
up to 60 minutes. The different drug treatments are marked by different colours with ‘X’ denoting no drug treatment.
and could be inhibited by the small molecule inhibitor.
Efficacy of erlotinib towards ErbB-2 dimers was previ-
ously mentioned by Schaefer et al. [61].
In BT474, the simulations resulted in active ERK1/2
states, resisting drug treatment (Table 1). In HCC1954
and SKBR3, the positive effect of erlotinib was supported
by the simulations. The attractor states were additionally
inactive for all other (combinatorial) drug treatments, but
not trastuzumab alone.
p70S6K is influenced by both, PI3K andMAPK, pathways
The target p70S6K is upstream influenced by the PI3K
as well as the MAPK pathway (Figure 2). Hence, p70S6K
merges both pathways, leading to activation of RPS6 [60].
The three cell lines showed different pathway prefer-
ences. BT474 required the combination of pertuzumab
and erlotinib to suppress p70S6K (Figure 5). On the con-
trary, in SKBR3 the triple drug combination was shown to
be optimal (Table 2). Obviously, the effect was driven by
erlotinib (Figure 4), which was supported by the attractor
states of p70S6K (Table 1). This resembled the drug
response of ERK1/2 and reflected a stronger influence by
the MAPK pathway. In HCC1954, deactivation of p70S6K
was reached via application of erlotinib combined with
pertuzumab (Table 2). The treatment with erlotinib alone
had a similar effect (Figure 6), while the simulations just
confirmed a positive effect of pertuzumab (Table 1). Thus,
this cell line seemed to be influenced by both, PI3K and
MAPK, pathways.
These results were in line with the newly inferred edges
in the network reconstructions. They pointed to a strong
influence of PI3K in BT474 in contrast to a dominant
MAPK pathway in SKBR3. HCC1954 was influenced by
both pathways to a similar extent.
To follow up on the hypothesis that different path-
ways contribute to a different extent in individual cell
lines, we tested correlation between the p70S6K time
course and the ones of AKT and ERK1/2, respectively.
In BT474, p70S6K correlated positively with AKT (p-
value 0.01, Kendall’s τ estimate 0.64). In HCC1954,
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Figure 6 HCC1954 short-term time courses of AKT, ERK1/2 and p70S6K. The figure shows splines and related standard error bars of the
measured RPPA data for AKT, ERK1/2 and p70S6K after combined EGF and HRG stimulation in the HCC1954 cell line. The measurements included
ten time points up to 60 minutes. The different drug treatments are marked by different colours with ‘X’ denoting no drug treatment.
p70S6K correlated positively with both, AKT (p-value <
2.22 · 10−16, Kendall’s τ estimate 0.69) and ERK1/2
(p-value < 2.22 · 10−16, Kendall’s τ estimate 0.87). In
SKBR3, p70S6K also correlated positively with both, AKT
(p-value 0.05, Kendall’s τ estimate 0.51) and ERK1/2
(p-value 0.02, Kendall’s τ estimate 0.6), with a stronger
tendency towards MAPK signalling. The correlation
was not as convincing as in the other two cell lines.
One could speculate, that the dominance of the MAPK
pathway in SKBR3 cells was not as strong as the domi-
nance of the PI3K pathway in BT474. This was supported
by the reconstructed networks. They revealed down-
Table 2 Optimal drug treatment in short-term signalling
Cell line AKT ERK1/2 p70S6K
BT474 - PE PE
HCC1954 PTE E PE
SKBR3 PTE E PTE
The table summarises the optimal drug treatments for the short-term data, leading to inactive AKT, ERK1/2 and p70S6K, respectively. In case of a significant (p-value<
0.05) combined influence of both, drug treatment and time, on the protein signal intensity, a Wilcoxon rank sum test was conducted for the measurements at time
point 60 minutes, testing for significantly (p-value< 0.05) smaller intensity values under the drug treatment compared to the control measurement. The drug
treatment with the smallest p-value was considered as the optimal inhibitor. No inferred significant positive drug effect is denoted by ‘-’. The therapeutics erlotinib,
trastuzumab and pertuzumab are abbreviated by their first letters. More than one letter denotes drug combinations. The growth factors EGF and HRG were added in
combination to the cell lines and permanently active in the simulated perturbation conditions. The column Cell line holds the cell lines under consideration. The
columns AKT, ERK1/2 and p70S6K hold the optimal drug combinations for each target. If those were confirmed by the attractor states (0) of perturbation simulations,
they are printed in bold.
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stream effects of MAPK signalling in SKBR3, while they
revealed hyperactive ErbB-2/3 dimers in BT474. The
dimers drive PI3K already at the receptor layer, and espe-
cially ErbB-2/3 dimers are regarded as the most potent
heterodimer [29].
Drug resistance in HCC1954 regarding the PI3K pathway
In HCC1954, the inferred optimal treatment against AKT
signalling with the triple drug combination was not con-
vincing (Figure 6). Analogously, Henjes et al. did not
monitor any positive drug effect on AKT under EGF appli-
cation alone [28]. However, the simulations suggested
pertuzumab alone or a combination of both monoclonal
antibodies to inhibit AKT phosphorylation. In principle,
divergence of simulations from experimental observations
can be expected, as the simulated steady state of the sys-
tem does not necessarily have to be reached after the
measured period of time. Anyhow, the apparent resis-
tance here pointed to a hyperactive PI3K pathway which
was explainable by the newly inferred HCC1954 edges
described in the previous subsection. They represented
feedback loops, hyperactive ErbB-1/2 heterodimers and
pathway crosstalk. On the contrary, in SKBR3, the triple
drug combination worked well, as described before. The
simulations even predicted efficacy of every other drug
(combination) apart from trastuzumab alone. The drug
efficacy towards AKT in this cell line could be explained
by the fact that the two reconstructed interactions in
SKBR3 mainly promoted the MAPK instead of the PI3K
pathway.
The regulation of AKT activity under drug influence,
highly diverging in HCC1954 and SKBR3, attracted our
attention. Therefore we intended testing for edgetic muta-
tions, as discussed by Zhong et al. [62], leading to AKT
gain-of-function in HCC1954. Such mutations, perturb-
ing not a node but an edge of a network, are speculated to
have deeper impact on phenotypic manifestation of a dis-
ease. In detail, we removed each of the AKT stimulating
edges outgoing from p70S6K, PDK1, mTOR and ErbB-
3, alone or in all possible eleven combinations. We then
computed the attractor states for the modified networks
in HCC1954.
Removal of the connections of mTOR, PDK1 and ErbB-3
alone or combined had no influence on improving drug
effects, i.e. AKT just got inactive under pertuzumab treat-
ment. Involvement of p70S6K→AKT in the withdrawal
process led to much better results. Removed alone or in
double combinations with the aforementioned edges, as
well as in the two triple combinations containing mTOR,
AKT was deactivated under all drug treatments, but not
yet trastuzumab alone. Finally, simultaneous removal of
the outgoing connections from p70S6K, ErbB-3 and PDK1
with or without mTOR, turned out as the only combina-
tion enabling potency of all possible drug combinations,
including trastuzumab alone. This hinted at a less strong
impact of mTOR on AKT here, but indicated synergistic
drug resistance potential of p70S6K, ErbB-3 and PDK1,
also due to the newly inferred edges.
Long-term signalling network reconstruction
The reconstructed long-term signalling networks per cell
line are displayed in the Additional file 6. Additional
file 5 lists the equivalent Boolean logical interaction
rules. Compared to the prior network, most of the
newly inferred edges were individual for each cell line,
but HCC1954 shared ErbB-1→ERK1/2 with SKBR3, for
example. This seemed to be an indirect edge via cRAF,
as represented in the prior network. Besides activat-
ing connections, also inhibiting ones and edge deletions
occurred. For HCC1954, ten new interactions were recon-
structed, while two were deleted. In BT474, nine new
links were added, and one edge was deleted. In SKBR3,
we inferred 20 new connections and one deletion, namely
the removal of p53 activation via p38, bearing oncogenic
risk [63,64].
In contrast to the short-term networks, new feedback
loops were reconstructed in every cell line, not exclu-
sively in HCC1954. In HCC1954, the mutual activation
between p53 and RB established such a feedback mecha-
nism. For SKBR3 we even inferred two edges, each form-
ing feedback loops. Contrary to HCC1954, p53 inhibited
RB. The second loop connection was inhibition of ErbB-
3 by AKT, pointing to a negative feedback against PI3K
signalling [65-67].
In HCC1954, the newly inferred edges Cyclin B1→AKT
and ErbB-3→ErbB-1 contributed to PI3K signalling, of
which the latter was explainable as heterodimers. The
newly inferred edge cJUN→ErbB-1 in HCC1954 also
indicated raised activity of ErbB-1. Interestingly, in SKBR3
we conducted an inhibiting edge from Cyclin B1 to AKT
but instead an activating one to ERK1/2, contributing to
MAPK signalling, which was also stated by Abrieu et al.
[68]. Another new edge in HCC1954 involved a cell cycle
player, i.e. activation of Cyclin D1 by p70S6K [69]. Accord-
ingly, we inferred RPS6→Cyclin D1 in BT474, with RPS6
as downstream target of p70S6K. In SKBR3, the edge
p70S6K→Cyclin B1 was reconstructed. A further inter-
esting new activating edge in HCC1954 led from RB to
TSC2, while we inferred a reversed inhibition in SKBR3.
Searle et al. discussed targeting RB deficient cancers by
deactivating TSC2 [70].
Two novel interactions in BT474 activated Cyclin B1,
arising from ErbB-1 and ErbB-3, respectively, which
meant that mitosis was driven by ErbB-1/3 dimers in this
cell line. This indicated a hyperactive PI3K pathway, as
revealed in the short-term case.
In SKBR3, we reconstructed an outgoing edge from
the artificial network stimulus S, representing full growth
von der Heyde et al. BMC Systems Biology 2014, 8:75 Page 14 of 21
http://www.biomedcentral.com/1752-0509/8/75
medium, activating AKT. This could be explained as
strong activation of AKT, driving PI3K signalling in
this cell line. The new edges ErbB-2→TSC2 and ErbB-
3→PRAS had to be interpreted as indirect effects, too.
They pointed to activity of ErbB-2/3 dimers, feeding
into both, MAPK and PI3K, pathways. The edge ErbB-
2→TSC2 could imply an oncogenic role of TSC2. Liu et al.
discussed a context dependent functionality of TSC2 [71].
Perturbation simulations on long-term networks
Similarly to the perturbation simulations for the short-
term networks, we performed those for the long-term
networks under all eight initial state combinations of the
therapeutics erlotinib, pertuzumab and trastuzumab. Also
here, all inferred attractors were simple and consisted of
one steady-state. Table 3 contains the simulation results
for the attractors of the RPS6 and RB proteins, as those
are key players in cell growth and proliferation and mainly
comparable to the experimental results of Henjes et al.
[28] for HCC1954 and SKBR3. We analysed the attractor
states of AKT and ERK1/2, too, but the results are not
explicitly listed, since they mostly resembled the ones of
RPS6.
The control measurements without any drug treatment
should result in activation of ErbB members and dimeri-
sation events, promoting cell growth and proliferation. In
fact, this was expressed as reasonable activation of AKT,
ERK1/2 and RPS6 in all cell lines, which held for simu-
lations as well as experimental observations. In contrast,
the attractor states of RB were inactive in all cell lines
(Table 3). Actually, a continuously rising stimulation effect
over 30 hours was not observed for HCC1954 and SKBR3
by Henjes et al. [28] either.
The attractor states of RPS6 and RB were identical in all
cell lines (Table 3). All drugs, except trastuzumab under
stimulation alone, led to inactive attractor states of RPS6.
This was also the case for ERK1/2 in all cell lines, as well
as AKT in BT474 and HCC1954. In SKBR3, the attractor
states of AKT were just inactive without the stimulus. All
therapeutics, including trastuzumab, resulted in deacti-
vated attractor states of RB. The statistically inferred drug
effects for AKT, ERK1/2, RB and RPS6 were slightly differ-
ent. Table 4 summarises the optimal drug combinations,
confirming and extending the observations of Henjes
et al. [28]. Most of them were supported by the perturba-
tion simulation results, corresponding to attractor states
of AKT, ERK1/2, RB and RPS6 being zero.
The optimal long-term drug response for AKT and ERK1/2
confirms short-term observations
As shown in Figure 7, the best drug response in BT474
and HCC1954 regarding AKT was yielded for a combina-
tion of trastuzumab and erlotinib. Statistically, we inferred
no positive effect in BT474 at all, which is explainable
by the fact that we just considered a combined effect of
drug treatment and time. Although the time courses of
AKT signalling with and without the drug treatment were
differing in the intensity strength, the signalling profiles
were similar. This parallel shift indicated no time effect.
Instead, the group effect was significant (p-value < 2 ·
10−16). This was also the explanation, why we detected
erlotinib, but not the combination with trastuzumab, as
the optimal treatment in HCC1954 (Table 4). In SKBR3,
we inferred the triple drug combination as the optimal
one, but the combination of both monoclonal antibodies
alone also had a significant effect over time (Figure 7).
Table 3 Attractor states of long-term perturbation simulations
BT474 HCC1954 SKBR3
Simulation RPS6 RB RPS6 RB RPS6 RB
A E A E A E A E A E A E
X 1 0 1 1 0 1 1 0 1
E 0 1 0 0 1 0 0 1 0
P 0 - 0 - 0 - 0 - 0 - 0 -
T 1 - 0 - 1 - 0 - 1 - 0 -
E, P 0 1 0 0 1 0 0 1 0
E, T 0 1 0 0 1 0 0 0
P, T 0 0 0 1 0 1 0 0
E, P, T 0 1 0 0 1 0 1 0 0
The therapeutics erlotinib, trastuzumab and pertuzumab, abbreviated by first letters, that were permanently active in the simulated perturbation conditions besides
the stimulus S, standing for the full growth medium, are stored in the column Simulation. No simulated drug treatment is denoted by ‘X’. The A columns hold the
attractor states of the proteins RPS6 and RB associated with the perturbations. The E columns contain the protein activity status, statistically deduced from the
experimental data. In case of a significant (p-value< 0.05) combined influence of both, drug treatment and time, on the protein signal intensity, a Wilcoxon rank sum
test was conducted for the measurements at time point 30 hours. The drug treatments leading to significantly (p-value< 0.05) smaller intensity values compared to
the control measurement ‘X’ were considered as efficient inhibitors, resulting in a table entry of zero. Lacking comparable experiments is labelled as ‘-’, while
consistency between simulations and experimental observations is printed in bold.
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Table 4 Optimal drug treatment in long-term signalling
Cell line AKT ERK1/2 RB RPS6
BT474 - TE E TP
HCC1954 E TE E -
SKBR3 PTE TE TE TE
The table summarises the optimal drug treatments for the long-term data,
leading to inactive AKT, ERK1/2, RB and RPS6, respectively. In case of a significant
(p-value< 0.05) combined influence of both, drug treatment and time, on the
protein signal intensity, a Wilcoxon rank sum test was conducted for the
measurements at time point 30 hours, testing for significantly (p-value< 0.05)
smaller intensity values under the drug treatment compared to the control
measurement. The drug treatment with the smallest p-value was considered as
the optimal inhibitor. No inferred significant positive drug effect is denoted by ‘-’.
The therapeutics erlotinib, trastuzumab and pertuzumab are abbreviated by
their first letters. More than one letter denotes drug combinations. The column
Cell line holds the cell lines under consideration. The columns AKT, ERK1/2, RB
and RPS6 hold the optimal drug combinations for each target. If those were
confirmed by the attractor states (0) of perturbation simulations, they are
printed in bold.
Hence, like in the short-term results, a drug combination
was required to suppress PI3K signalling, here with an
obvious need for trastuzumab. For BT474 and HCC1954,
this was supported by the simulation results, in which
trastuzumab alone had no effect, but was efficient within
drug combinations. In HCC1954, even the best drug
response was not convincing (Figure 7), pointing to a
dominant PI3K pathway, as revealed in the short-term
analysis.
Interestingly, SKBR3 showed a strong activation peak of
AKT phosphorylation between 8 and 18 hours (Figure 7),
which was just suppressed under combined application of
trastuzumab and pertuzumab. We revealed a positive cor-
relation with ERK1/2 (p-value 0.02, Kendall’s τ estimate
0.6) and RPS6 (p-value 0.01, Kendall’s τ estimate 0.64).
The reconstructed edges S→AKT and ErbB-1→ERK1/2
in SKBR3 indicated strong activation of AKT and ERK1/2.
In addition to the prior network, in which AKT and
ERK1/2 fed into RPS6 phosphorylation via p70S6K, some
of the novel edges pointed to a positive feedback from
p70S6K or RPS6 to ERK1/2. The feedback from p70S6K
via Cyclin B1, for example, was expressed by the edges
p70S6K→Cyclin B1 and Cyclin B1→ERK1/2. Compared
to the short-term results, indicating a dominant MAPK
pathway, this long-term observation indicated strong sig-
nalling via both, PI3K and MAPK, pathways in SKBR3.
As displayed in Figure 8, erlotinib alone or in combina-
tion with trastuzumab showed the optimal effect against
ERK1/2 in all of the three cell lines. This was in line
with the short-term observations, and confirmed by the
Figure 7 Long-term time courses of AKT for all cell lines. The figure shows splines and related standard error bars of the measured RPPA data for
AKT in all cell lines. The measurements included ten time points up to 30 hours. The different drug treatments are marked by different colours with
‘X’ denoting no drug treatment.
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Figure 8 Long-term time courses of ERK1/2 for all cell lines. The figure shows splines and related standard error bars of the measured RPPA data
for ERK1/2 in all cell lines. The measurements included ten time points up to 30 hours. The different drug treatments are marked by different colours
with ‘X’ denoting no drug treatment.
perturbation simulations. Statistically, the most potent
drug effect was yielded with the combination of erlotinib
and trastuzumab (Table 4).
Quick drug response for RPS6 and delayed response for RB
As shown in Figure 9, in BT474, the simulation based
predicted efficacy of erlotinib alone to counteract RPS6
(Table 3) was not as convincing as in case of drug combi-
nations. A combination of pertuzumab and trastuzumab
worked best (Table 4). For RB, the simulated drug
effects in BT474 resembled the observed ones (Table 3,
Figure 10), with a positive effect of all measured drug
treatments. Erlotinib was inferred as the optimal treat-
ment (Table 4). Though, the drug impact unfolded not
before 18 hours.
In HCC1954, it was the combination of both mon-
oclonal antibodies, that failed in deactivating RPS6
(Figure 9), while the simulations predicted trastuzumab
alone to fail (Table 3). The graphical observations were
similar for RB (Figure 10). The newly inferred edges ErbB-
3→ErbB-1 and cJUN→ErbB-1 in HCC1954 explained the
necessity for erlotinib against ErbB-1 dimers. The positive
impact of erlotinib, the optimal treatment against RB sig-
nalling (Table 4), was supported by simulations. However,
it did not unfold before 12-18 hours, in case of RB as
well as RPS6. Regarding RPS6, no significant effect was
detected for HCC1954 (Table 4).
According to Henjes et al. [28], in SKBR3 erlotinib and
all therapeutic combinations helped to suppress RPS6,
which was supported by the simulations (Table 3). As
shown in Figure 9, the combination of trastuzumab and
erlotinib was the only one, that revealed its continuous
inhibiting effect already after one hour. This combined
treatment was also statistically inferred as the optimal one
(Table 4). The same combination was optimal with respect
to RB activity, which was also in line with the simulations.
Here, analogously to BT474 and HCC1954, the drug effect
did not appear before 18 hours (Figure 10).
As the combination of trastuzumab and erlotinib was
efficient in all of the three cell lines against RPS6 as well
as RB phosphorylation, we further analysed target correla-
tions under this drug combination to explain the different
rapidness of drug responses.
In BT474, RB positively correlated with Cyclin B1 (p-
value 0.02, Kendall’s τ estimate 0.6), while RPS6 positively
correlated with ERK1/2 (p-value 0.02, Kendall’s τ esti-
mate 0.6). Obviously, RPS6 was mainly stimulated by
the MAPK pathway, which was efficiently inhibited by
the combination of trastuzumab and erlotinib in a fast
manner. On the contrary, RB seemed to be influenced
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Figure 9 Long-term time courses of RPS6 for all cell lines. The figure shows splines and related standard error bars of the measured RPPA data
for RPS6 in all cell lines. The measurements included ten time points up to 30 hours. The different drug treatments are marked by different colours
with ‘X’ denoting no drug treatment.
by Cyclin B1. The newly reconstructed edges ErbB-
1→Cyclin B1 and ErbB-3→Cyclin B1 supported hyper-
activity of Cyclin B1, driven by ErbB-1/3 heterodimers.
In SKBR3, RB negatively correlated with PRAS (p-value
0.05, Kendall’s τ estimate -0.51) and TSC2 (p-value 0.03,
Kendall’s τ estimate -0.56), while RPS6 positively corre-
lated with AKT (p-value 0.03, Kendall’s τ estimate 0.56)
and ERK1/2 (p-value 0.02, Kendall’s τ estimate 0.6). Obvi-
ously, like in BT474, RPS6 was mainly activated through
the MAPK pathway. Interestingly, RB seemed to require
inhibition via PRAS or TSC2. The latter was confirmed
via one of the novel edges in SKBR3, namely inhibition of
RB by TSC2. In addition, PRAS as well as TSC2 seemed to
be especially active in this cell line with regard to the new
edges ErbB-3→PRAS and ErbB-2→TSC2.
In HCC1954, the drug response was not only delayed
for RB, but also for RPS6, which was in line with the posi-
tive correlation with RB (p-value < 2.22 · 10−16, Kendall’s
τ estimate 0.73). Like in BT474, Cyclin B1 seemed to be a
driving force, since both, RPS6 (p-value 0.03, Kendall’s τ
estimate 0.56) and RB (p-value < 2.22 · 10−16, Kendall’s
τ estimate 0.82) positively correlated with this target. The
new edge Cyclin B1→AKT supported special activation
of RPS6 via PI3K signalling, leading to a delayed drug
response. Interestingly, we revealed negative correlations,
as observed for SKBR3. In HCC1954, RPS6 and RB corre-
lated with BAX (p-value 0.03, Kendall’s τ estimate -0.56)
and FoxO1/3a (p-value 0.05, Kendall’s τ estimate -0.51),
pointing to a delayed inhibition of RPS6 and RB via BAX
or FoxO1/3a.
Conclusions
Using a combination of reverse and forward engineer-
ing techniques, we focused on deregulated protein inter-
actions in the ErbB network in a Boolean modelling
framework. The reconstructed hypothetical networks
revealed individual protein interactions contributing to
signalling pathway preferences as well as drug resistance
via feedback loops, pathway crosstalk or hyperactive het-
erodimers. While this reverse engineering focused on
the network edges, we concentrated in the subsequent
forward engineering step on the network nodes. The per-
turbation simulations for AKT, ERK1/2, RB and RPS6
mainly confirmed our graphical and statistical analy-
ses as well as the observations of Henjes et al. [28]
regarding (combinatorial) drug efficacy. However they
have to be interpreted as an independent, more prospec-
tive investigation, because stable system states do not
necessarily have to be reached in temporally limited
observations.
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Figure 10 Long-term time courses of RB for all cell lines. The figure shows splines and related standard error bars of the measured RPPA data for
RB in all cell lines. The measurements included ten time points up to 30 hours. The different drug treatments are marked by different colours with ‘X’
denoting no drug treatment.
In the first step, the combined Boolean modelling
approach revealed the mechanisms underlying individual
drug response. In the second step, it predicted the net-
work propagation effects on protein activity, and hence
the drug response itself.
Onemajor finding is, that different breast cancer pheno-
types seem to be driven by specific pathway preferences in
the ErbB network. This leads to individual drug response,
requiring different therapeutic treatments. The perturba-
tion simulations revealed a more diverse drug response
in short-term than in long-term signalling, which stresses
the importance of early intervention at the top level layer
of the signalling network.
Another interesting aspect is to combine edge and
node perturbations in Boolean network models to reveal
edgetic mutations, as we did in the HCC1954 cell line for
AKT.
Basic molecular research, embedded in a Boolean mod-
elling framework here, composes a first step to gain insight
into individual mechanisms of drug response or resistance
mechanisms in breast cancer. Especially, the proteomic
signalling interplay directly effects tumour development
and represents a promising target in cancer therapy, which
has to be understood in more detail in the future.
Additional files
Additional file 1: Proteins and phosphorylation sites involved in
RPPAmeasurements. The tables show the proteins and phosphorylation
sites involved in RPPA short- and long-term measurements. The antibody
catalogue numbers and providing companies are mentioned in brackets.
For BT474, no experimental short-term data under EGF or HRG stimulation
were available for PDK1. In case of total protein measurements, the column
Phosphosite remains empty (‘-’) apart from the antibody number and
supplier name.
Additional file 2: Literature references for the prior networks of
short- and long-term signalling. The interactions between proteins are
listed line by line in the tables. The column Protein denotes the source of
the connection with the sink called Target. The interaction (Type) is
encoded numerically, i.e. activation is marked by 1, while inhibition is
labelled with 2, e.g. AKT activates mTOR. The column Reference specifies
the supportive publication.
Additional file 3: Workflow of MCMC-based network structure
inference. The inhibMCMC procedure of the ddepn package was run with
maxIter = 50, 000 in 10 parallel runs. The results of the 25,000 iterations
after the burn-in phase were merged into one consensus network. It was
applied for short- and long-term data separately per cell line, leading to six
consensus networks. The figure is based on [6,47].
Additional file 4: Edge confidences for the reconstructed networks of
the three cell lines per time course. In each of the ten MCMC runs,
activation and inhibition edges were sampled. The percentage, i.e. the
confidence, of sampled activation (red) and inhibition (blue) edges in the
25,000 iterations after the burn-in phase are depicted in the boxes. The sink
nodes are displayed in each panel, while the activating, inhibiting or
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missing influence of the source nodes is shown column-wise in the red,
blue or missing boxes. The source node names are displayed at the x-axis
with additional indicators, where ‘-’ refers to an inhibiting influence and ‘+’
is related to activation. The x-axis of the short-term plots is labelled as ‘AKT,
E, EGF, ERBB1, ERBB2, ERBB3, ERK1/2, HRG, MEK1/2, mTOR, P, p70S6K, PDK1,
PKCα, PLCγ , T’. The x-axis of the long-term plots is labelled as ‘AKT, BAX,
cJUN, cRAF, CyclinB1, CyclinD1, E, ERBB1, ERBB2, ERBB3, ERK1/2, FOXO1/3a,
GSK3α/β , NF-κB, P, p38, p53, p70S6K, PRAS, PTEN, RB, S, RPS6, T, TSC2’. An
activating edge in the consensus network, as described in Additional file 3,
means that the sampled activating edges have a significantly higher
confidence value than the inhibiting ones. As self-loops and ingoing edges
to the drug or growth factor nodes were not allowed during inference, the
respective confidences are zero.
Additional file 5: Boolean interaction rules for the components of the
short- and long-term signalling networks. The tables contain the rules
that arose from network reconstructions based on short- and long-term
RPPA data of BT474, HCC1954 and SKBR3. The three drug names erlotinib,
trastuzumab and pertuzumab are abbreviated via their first letters. For the
long-term networks, the stimulus is denoted by S. Symbols are
interpretable in the following way: & ≡ AND, ∨ ≡ OR and ! ≡ NOT.
Additional file 6: Reconstructed long-term signalling networks. The
figure displays the reconstructed long-term signalling networks for BT474,
HCC1954 and SKBR3. Target proteins are represented as rectangles with
stimulus and drugs coloured in red. The three drug names erlotinib,
trastuzumab and pertuzumab are abbreviated via their first letters.
Stimulation via full growth medium is denoted by S. Solid arrows denote
activating interactions while dashed ones represent inhibitions.
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